Stefanie Huhn

Head of Laboratory

UniversitätsKlinikum Heidelberg

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Stefanie Huhn is the Head of Laboratory at UniversitätsKlinikum Heidelberg, Klinik für Hämatologie Onkologie und Rheumatologie in Germany. Her research areas focus on multiple myeloma and AL amyloidosis, with recent publications exploring the implications of mass spectrometry, genetic variants, and therapeutic strategies for newly diagnosed patients. She investigates prognostic factors and the molecular mechanisms underlying these diseases.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (2)

Joanna Blocka

Dana-Farber Cancer Institute

UNITED STATES

View details

Ute Hegenbart

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Stefanie Huhn

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Identification of AL proteins from 10 λ-AL amyloidosis patients by mass spectrometry extracted from abdominal fat and heart tissue

Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Investigation of Rare Non-Coding Variants in Familial Multiple Myeloma.

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement

Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis

Search for AL amyloidosis risk factors using Mendelian randomization

Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21

Collaborators (2)

Joanna Blocka

Ute Hegenbart

Make your next move.